Search results
May 14, 2024 · Sobi develops and provides innovative medicines for people with rare and debilitating conditions. Learn about their pipeline, investor relations, media, and stories of patients and partners.
- About
About us Sobi is a specialised international...
- Disease areas
Summary of Sobi’s therapeutic areas – haematology and...
- Key medicines
Alprolix ® * (eftrenonacog alfa). Alprolix ® (eftrenonacog...
- Stories
Patients and science lie at the heart of everything we do....
- Investors
Sobi is a specialised international biopharmaceutical...
- Media
Media | Press releases Press releases 19 June, 2024 08:00...
- Partnership
Partnership At Sobi, we work with a range of partners to...
- Immunology
Immunology Our immune system is vital in protecting us from...
- About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden. In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.
Sobi’s R&D pipeline: colour-coded chart showing haematology, immunology, and specialty care treatments in phases 1, 2 and 3 and at the registration stage.
2 days ago · Stock analysis for Swedish Orphan Biovitrum AB (SOBI:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
- 1.8K
Find the latest Swedish Orphan Biovitrum AB (publ) (BIOVF) stock quote, history, news and other vital information to help you with your stock trading and investing.
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We provide sustainable access to innovative therapies in the areas of haematology,...